{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:13:54Z","timestamp":1792548834266,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T00:00:00Z","timestamp":1510272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00403-017-1792-6","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T06:37:45Z","timestamp":1510295865000},"page":"39-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case\u2013control study"],"prefix":"10.1007","volume":"310","author":[{"given":"Hanan Rabea","family":"Nada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Ahmed","family":"El Sharkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-3897","authenticated-orcid":false,"given":"Maha Fathy","family":"Elmasry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila Ahmed","family":"Rashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mamdouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,10]]},"reference":[{"issue":"5573","key":"1792_CR1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1071545","volume":"296","author":"DS Aaronson","year":"2002","unstructured":"Aaronson DS, Horvath CM (2002) A road map for those who don\u2019t know JAK-STAT. Science 296(5573):1653\u20131655","journal-title":"Science"},{"key":"1792_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/exd.12128","volume":"22","author":"RM Andr\u00e9s","year":"2013","unstructured":"Andr\u00e9s RM, Hald A, Johansen C, Kragballe K, Iversen L (2013) Studies of Jak\/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Exp Dermatol 22:323\u2013328. \n                        https:\/\/doi.org\/10.1111\/exd.12128","journal-title":"Exp Dermatol"},{"key":"1792_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00403-012-1269-6","volume":"304","author":"E Attwa","year":"2012","unstructured":"Attwa E, Gamil H, Assaf M, Ghonemy S (2012) Over-expression of tumor necrosis factor-\u03b1 in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study. Arch Dermatol Res 304:823\u2013830. \n                        https:\/\/doi.org\/10.1007\/s00403-012-1269-6","journal-title":"Arch Dermatol Res"},{"key":"1792_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev.immunol.15.1.563","volume":"15","author":"EA Bach","year":"1997","unstructured":"Bach EA, Aguet M, Schreiber RD (1997) The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563\u2013591. \n                        https:\/\/doi.org\/10.1146\/annurev.immunol.15.1.563","journal-title":"Annu Rev Immunol"},{"key":"1792_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/j.1468-3083.2008.02681.x","volume":"22","author":"PY Basak","year":"2008","unstructured":"Basak PY, Adiloglu AK, Koc IG, Tas T, Akkaya VB (2008) Evaluation of activatory and inhibitory natural killer cell receptors in non-segmental vitiligo: a flow cytometric study. J Eur Acad Dermatol Venereol 22:970\u2013976. \n                        https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02681.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1792_CR6","first-page":"273","volume":"41","author":"SB Bhise","year":"2004","unstructured":"Bhise SB, Nalawade AD, Wadhawa H (2004) Role of protein tyrosine kinase inhibitors in cancer therapeutics. Indian J Biochem Biophys 41(6):273\u2013280","journal-title":"Indian J Biochem Biophys"},{"key":"1792_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"BG Craiglow","year":"2015","unstructured":"Craiglow BG, King BA(2015)Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol151:1110\u20131112. \n                        https:\/\/doi.org\/10.1001\/jamadermatol.2015.1520","journal-title":"JAMA Dermatol"},{"key":"1792_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S82599","volume":"10","author":"V Lernia Di","year":"2016","unstructured":"Di Lernia V, Bardazzi F (2016) Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther 10:533\u2013539. \n                        https:\/\/doi.org\/10.2147\/DDDT.S82599","journal-title":"Drug Des Devel Ther"},{"key":"1792_CR9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1189\/jlb.0212101","volume":"92","author":"MM Elloso","year":"2012","unstructured":"Elloso MM, Gomez-Angelats M, Fourie AM (2012) Targeting the Th17 pathway in psoriasis. J Leukoc Biol 92:1187\u20131197. \n                        https:\/\/doi.org\/10.1189\/jlb.0212101","journal-title":"J Leukoc Biol"},{"issue":"8","key":"1792_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen SL (2009) Structure and signaling in the IL-17 receptor family. Nat Rev Immunol 9(8):556\u2013567. \n                        https:\/\/doi.org\/10.1038\/nri2586","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1792_CR11","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14656566.2016.1195812","volume":"17","author":"M Galluzzo","year":"2016","unstructured":"Galluzzo M, D\u2019Adamio S, Servoli S, Bianchi L, Chimenti S, Talamonti M (2016) Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother 17(10):1421\u20131433. \n                        https:\/\/doi.org\/10.1080\/14656566.2016.1195812","journal-title":"Expert Opin Pharmacother"},{"key":"1792_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273\u2013287. \n                        https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00754.x","journal-title":"Immunol Rev"},{"key":"1792_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H (2004) Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 140:677\u2013683. \n                        https:\/\/doi.org\/10.1001\/archderm.140.6.677","journal-title":"Arch Dermatol"},{"issue":"2","key":"1792_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J (2016) Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol 74(2):370\u2013371. \n                        https:\/\/doi.org\/10.1016\/j.jaad.2015.09.073","journal-title":"J Am Acad Dermatol"},{"key":"1792_CR15","doi-asserted-by":"publisher","unstructured":"Hsu L, Armstrong AW (2014) JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res 2014: 283617. \n                        https:\/\/doi.org\/10.1155\/2014\/283617","DOI":"10.1155\/2014\/283617"},{"key":"1792_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4049\/jimmunol.1003244","volume":"187","author":"M Ishizaki","year":"2011","unstructured":"Ishizaki M, Akimoto T, Muromoto R, Yokoyama M, Ohshiro Y, Sekine Y, Maeda H, Shimoda K, Oritani K, Matsuda T (2011) Involvement of tyrosine kinase-2 in both the IL-12\/Th1 and IL-23\/Th17 axes in vivo. J Immunol 187:181\u2013189. \n                        https:\/\/doi.org\/10.4049\/jimmunol.1003244","journal-title":"J Immunol"},{"key":"1792_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","volume":"23","author":"J Klarquist","year":"2010","unstructured":"Klarquist J, Denman CJ, Hernandez C, Wainwright DA, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC (2010) Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 23:276\u2013286. \n                        https:\/\/doi.org\/10.1111\/j.1755-148X.2010.00688.x","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"1792_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2340\/00015555-1931","volume":"95","author":"K Kofoed","year":"2015","unstructured":"Kofoed K, Skov L, Zachariae C (2015) New drugs and treatment targets in psoriasis. Acta Derm Venereol 95(2):133\u2013139. \n                        https:\/\/doi.org\/10.2340\/00015555-1931","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1792_CR19","first-page":"913","volume":"11","author":"SG Kwatra","year":"2012","unstructured":"Kwatra SG, Dabade TS, Gustafson CJ, Feldman SR (2012) JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol 11(8):913\u2013918","journal-title":"J Drugs Dermatol"},{"key":"1792_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.drup.2010.04.001","volume":"13","author":"SY Lai","year":"2010","unstructured":"Lai SY, Johnson FM (2010) Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Update 13:67\u201378. \n                        https:\/\/doi.org\/10.1016\/j.drup.2010.04.001","journal-title":"Drug Resist Update"},{"key":"1792_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-017-3017-x","author":"DA Landry","year":"2017","unstructured":"Landry DA, Sormany F, Hach\u00e9 J, Roumaud P, Martin LJ (2017) Steroidogenic genes expressions are repressed by high levels of leptin and the JAK\/STAT signaling pathway in MA-10 Leydig cells. Mol Cell Biochem. \n                        https:\/\/doi.org\/10.1007\/s11010-017-3017-x","journal-title":"Mol Cell Biochem"},{"key":"1792_CR22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/bjd.14399","volume":"174","author":"VJ Ludbrook","year":"2016","unstructured":"Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, Watson J, Wilson P, Simeoni M, Schifano LA, Reich K, Griffiths CE (2016) Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol 174:985\u2013995. \n                        https:\/\/doi.org\/10.1111\/bjd.14399","journal-title":"Br J Dermatol"},{"key":"1792_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/archderm.1989.01670140087017","volume":"125","author":"R Marks","year":"1989","unstructured":"Marks R, Barton SP, Shuttleworth D, Finlay AY (1989) Assessment of disease progress in psoriasis. Arch Dermatol 125:235\u2013240. \n                        https:\/\/doi.org\/10.1001\/archderm.1989.01670140087017","journal-title":"Arch Dermatol"},{"key":"1792_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.adengl.2013.03.002","volume":"104","author":"K Ortiz-Ib\u00e1\u00f1ez","year":"2013","unstructured":"Ortiz-Ib\u00e1\u00f1ez K, Alsina MM, Mu\u00f1oz-Santos C (2013) Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiligor 104:304\u2013310. \n                        https:\/\/doi.org\/10.1016\/j.adengl.2013.03.002","journal-title":"Actas Dermosifiligor"},{"issue":"6","key":"1792_CR25","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","volume":"174","author":"KA Papp","year":"2016","unstructured":"Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, Macias W, Zhang X, Janes JM (2016) A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 174(6):1266\u20131276. \n                        https:\/\/doi.org\/10.1111\/bjd.14403","journal-title":"Br J Dermatol"},{"issue":"4","key":"1792_CR26","doi-asserted-by":"publisher","first-page":"65864","DOI":"10.1016\/j.jaad.2011.12.018","volume":"67","author":"N Punwani","year":"2012","unstructured":"Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A (2012) Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 67(4):658\u201364. \n                        https:\/\/doi.org\/10.1016\/j.jaad.2011.12.018","journal-title":"J Am Acad Dermatol"},{"key":"1792_CR27","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1038\/sj.onc.1203925","volume":"19","author":"SG Rane","year":"2000","unstructured":"Rane SG, Reddy EP (2000) Janus kinases: components of multiple signaling pathways. Oncogene 19:5662\u20135679. \n                        https:\/\/doi.org\/10.1038\/sj.onc.1203925","journal-title":"Oncogene"},{"key":"1792_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.semcdb.2008.08.010","volume":"19","author":"C Schindler","year":"2008","unstructured":"Schindler C, Plumlee C (2008) Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 19:311\u2013318. \n                        https:\/\/doi.org\/10.1016\/j.semcdb.2008.08.010","journal-title":"Semin Cell Dev Biol"},{"key":"1792_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1468-3083.2011.04368.x","volume":"27","author":"Seif El Nasr","year":"2013","unstructured":"Nasr Seif El, Shaker H, Fawzi OG, El-Hanafi MM G (2013) Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets. J Eur Acad Dermatol Venereol 27:103\u2013108. \n                        https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04368.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1792_CR30","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","volume":"191","author":"SJ Sohn","year":"2013","unstructured":"Sohn SJ, Barrett K, Van Abbema A, Chang C, Kohli PB, Kanda H, Smith J, Lai Y, Zhou A, Zhang B, Yang W et al (2013) A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 191:2205\u20132216. \n                        https:\/\/doi.org\/10.4049\/jimmunol.1202859","journal-title":"J Immunol"},{"key":"1792_CR31","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG Boorn van den","year":"2009","unstructured":"van den Boorn JG, Konijnenberg D, Dellemijn TA, van der Veen JP, Bos JD, Melief CJ, Vyth-Dreese FA, Luiten RM (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129:2220\u20132232. \n                        https:\/\/doi.org\/10.1038\/jid.2009.32","journal-title":"J Invest Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-017-1792-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-017-1792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-017-1792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T02:58:29Z","timestamp":1515034709000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-017-1792-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,10]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1007\/s00403-017-1792-6","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,10]]}}}